Shamburg News · 8-K filed Nov 10, 2026, 5:06 PM EST

Cumberland Pharmaceuticals Reports Q3 2026 Results and Company Update Following Strategic Transaction

CPIX · CUMBERLAND PHARMACEUTICALS INC

  • Earnings
  • Other event
  • Materiality: high

Cumberland Pharmaceuticals Inc. reported financial results for the three and nine months ended September 30, 2026, including net income of $77.8 million for the quarter, which included a gain on divestiture of the assets tied to its Strategic Transaction with Apotex Health. The company reported approximately $114 million in total assets, including $80.6 million in cash and cash equivalents, as of September 30, 2026. The release also announced a decision to submit a New Drug Application for ifetroban in Duchenne muscular dystrophy cardiomyopathy and top-line results from a Phase 2a trial in systemic sclerosis.

Read the filing on EDGAR ↗

Source: SEC EDGAR, Form 8-K, Item 2.02, accession 0001087294-26-000076.

Written from the filing by Shamburg Markets. Figures are as reported by the company.